Autoimmune inner ear disease: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Autoimmune inner ear disease | |||
| image = [[File:Cochlea-crosssection.svg|250px]] | |||
| caption = Cross-section of the [[cochlea]], a part of the [[inner ear]] | |||
| field = [[Otorhinolaryngology]] | |||
| symptoms = [[Hearing loss]], [[tinnitus]], [[vertigo]] | |||
| onset = Typically [[adulthood]] | |||
| duration = [[Chronic (medicine)|Chronic]] | |||
| causes = [[Autoimmune disease]] | |||
| risks = [[Genetic predisposition]], [[environmental factors]] | |||
| diagnosis = [[Audiometry]], [[blood test]] for [[autoantibodies]], [[MRI]] | |||
| differential = [[Ménière's disease]], [[otitis media]], [[acoustic neuroma]] | |||
| treatment = [[Corticosteroids]], [[immunosuppressants]], [[hearing aids]] | |||
| prognosis = Variable, can lead to permanent [[hearing loss]] | |||
| frequency = Rare | |||
}} | |||
'''Other Names:''' AIED | '''Other Names:''' AIED | ||
Autoimmune inner ear disease (AIED) has been defined as a condition of bilateral sensorineural hearing loss (SNHL), caused by an ‘uncontrolled’ immune system response. | |||
Autoimmune inner ear disease (AIED) has been defined as a condition of bilateral sensorineural hearing loss (SNHL), caused by an | |||
The inner ear can be the direct target of the immune response, but it can be additionally damaged by a deposition of circulating immune complexes or by systemic immune-mediated diseases. | The inner ear can be the direct target of the immune response, but it can be additionally damaged by a deposition of circulating immune complexes or by systemic immune-mediated diseases. | ||
== '''Epidemiology''' == | == '''Epidemiology''' == | ||
The estimated yearly incidence of AIED is <5 cases per 100,000 and its estimated prevalence is about 15/100,000 (in the United States, the expected annual AIED prevalence is 45,000 patients); it is reported that AIED is more prevalent in women, in their third and the sixth decades of life. | The estimated yearly incidence of AIED is <5 cases per 100,000 and its estimated prevalence is about 15/100,000 (in the United States, the expected annual AIED prevalence is 45,000 patients); it is reported that AIED is more prevalent in women, in their third and the sixth decades of life. | ||
== '''Cause''' == | == '''Cause''' == | ||
AIED is generally caused by either [[antibodie]]s or [[immune cells]] that cause damage to the inner ear. There are several theories that propose a cause of AIED: | AIED is generally caused by either [[antibodie]]s or [[immune cells]] that cause damage to the inner ear. There are several theories that propose a cause of AIED: | ||
'''Bystander damage''' – Physical damage to the inner ear may lead to [[cytokine]] release that signals for an immune response. This may be a component of the "attack/remission cycle" of [[Meniere's disease]]. | |||
'''Bystander damage''' | '''Cross-reactions''' – Accidental damage of the inner ear by antibodies or [[T-cells]] that recognize an inner ear antigen that is similar to a bacterial or viral antigen | ||
'''Cross-reactions''' | '''Genetic factors''' – Predisposition to developing an [[autoimmune disorder]] based on genes inherited | ||
'''Genetic factors''' | '''Intolerance''' – The immune system may not be aware of all the antigens present in the inner ear until physical damage releases some of these antigens. As a result, the immune system treats these unfamiliar antigens as foreign and mounts an immune response. | ||
'''Intolerance''' | |||
Currently, the cross-reactions theory appears to be the favored mechanism of AIED pathogenesis. | Currently, the cross-reactions theory appears to be the favored mechanism of AIED pathogenesis. | ||
== '''Signs and symptoms''' == | == '''Signs and symptoms''' == | ||
Signs and symptoms of AIED are: | Signs and symptoms of AIED are: | ||
| Line 25: | Line 37: | ||
* Loss of balance (vestibular symptoms) | * Loss of balance (vestibular symptoms) | ||
* Degree of balance loss can change throughout the course of the disease | * Degree of balance loss can change throughout the course of the disease | ||
== '''Diagnosis''' == | == '''Diagnosis''' == | ||
Since AIED symptoms are fairly common to many hearing loss disorders, it may be difficult to diagnose AIED without performing multiple medical tests. Some examples of these tests include: | Since AIED symptoms are fairly common to many hearing loss disorders, it may be difficult to diagnose AIED without performing multiple medical tests. Some examples of these tests include: | ||
| Line 35: | Line 46: | ||
* [[Erythrocyte sedimentation rate]] (test for inflammation) | * [[Erythrocyte sedimentation rate]] (test for inflammation) | ||
* [[Rheumatoid Factor]] (indicator of autoimmune disorders) | * [[Rheumatoid Factor]] (indicator of autoimmune disorders) | ||
There are also blood tests specific to inner ear disorders: | There are also blood tests specific to inner ear disorders: | ||
* [[Anti-cochlear antibody test]] (testing for antibodies against cochlear cells) | * [[Anti-cochlear antibody test]] (testing for antibodies against cochlear cells) | ||
* [[Lymphocyte Transformation Assay]] (testing whether an individual has developed a T-cell response against a certain drug) | * [[Lymphocyte Transformation Assay]] (testing whether an individual has developed a T-cell response against a certain drug) | ||
Though it has also been proposed that the use of anti heat shock protein 70 antibodies may be useful in the detection and diagnosis of AIED. | Though it has also been proposed that the use of anti heat shock protein 70 antibodies may be useful in the detection and diagnosis of AIED. | ||
== '''Treatment''' == | == '''Treatment''' == | ||
AIED treatment is a rapidly changing field. Several medical therapies have been proposed in the treatment of AIED, with [[corticosteroid]] therapy being the most effective. However, corticosteroid therapy (specifically with [[prednisone]] and [[dexamethasone]]) has demonstrated limited effectiveness in some patients, suggesting the need for novel treatment methods. | AIED treatment is a rapidly changing field. Several medical therapies have been proposed in the treatment of AIED, with [[corticosteroid]] therapy being the most effective. However, corticosteroid therapy (specifically with [[prednisone]] and [[dexamethasone]]) has demonstrated limited effectiveness in some patients, suggesting the need for novel treatment methods. | ||
The goal of most AIED treatments is to administer [[corticosteroids]] over a certain period of time, re-evaluate hearing at each appointment, and eventually taper off corticosteroid administration. Ideally, patients can be tapered off with hearing fully recovered, though this is the least likely outcome. | The goal of most AIED treatments is to administer [[corticosteroids]] over a certain period of time, re-evaluate hearing at each appointment, and eventually taper off corticosteroid administration. Ideally, patients can be tapered off with hearing fully recovered, though this is the least likely outcome. | ||
Often, [[tumor necrosis factor-α]] (TNF-α) inhibitors must be administered alongside corticosteroids to achieve a favorable outcome and eventual end to corticosteroid treatment. Recent papers have indicated that the '''[[TNF-α inhibitor]]''',''' [[infliximab]]''', has the potential to allow for sustained patient improvement and alleviation of symptoms. | |||
Often, [[tumor necrosis factor- | |||
Cytotoxic agents such as '''[[cyclophosphamide]]''' and '''[[methotrexate]]''' have been used in AIED treatment in the past; however, findings have suggested limited symptom alleviation from these drugs. | Cytotoxic agents such as '''[[cyclophosphamide]]''' and '''[[methotrexate]]''' have been used in AIED treatment in the past; however, findings have suggested limited symptom alleviation from these drugs. | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
| Line 53: | Line 59: | ||
{{rarediseases}} | {{rarediseases}} | ||
{{stub}} | {{stub}} | ||
Latest revision as of 16:49, 4 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Autoimmune inner ear disease | |
|---|---|
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Hearing loss, tinnitus, vertigo |
| Complications | N/A |
| Onset | Typically adulthood |
| Duration | Chronic |
| Types | N/A |
| Causes | Autoimmune disease |
| Risks | Genetic predisposition, environmental factors |
| Diagnosis | Audiometry, blood test for autoantibodies, MRI |
| Differential diagnosis | Ménière's disease, otitis media, acoustic neuroma |
| Prevention | N/A |
| Treatment | Corticosteroids, immunosuppressants, hearing aids |
| Medication | N/A |
| Prognosis | Variable, can lead to permanent hearing loss |
| Frequency | Rare |
| Deaths | N/A |
Other Names: AIED
Autoimmune inner ear disease (AIED) has been defined as a condition of bilateral sensorineural hearing loss (SNHL), caused by an ‘uncontrolled’ immune system response.
The inner ear can be the direct target of the immune response, but it can be additionally damaged by a deposition of circulating immune complexes or by systemic immune-mediated diseases.
Epidemiology[edit]
The estimated yearly incidence of AIED is <5 cases per 100,000 and its estimated prevalence is about 15/100,000 (in the United States, the expected annual AIED prevalence is 45,000 patients); it is reported that AIED is more prevalent in women, in their third and the sixth decades of life.
Cause[edit]
AIED is generally caused by either antibodies or immune cells that cause damage to the inner ear. There are several theories that propose a cause of AIED: Bystander damage – Physical damage to the inner ear may lead to cytokine release that signals for an immune response. This may be a component of the "attack/remission cycle" of Meniere's disease. Cross-reactions – Accidental damage of the inner ear by antibodies or T-cells that recognize an inner ear antigen that is similar to a bacterial or viral antigen Genetic factors – Predisposition to developing an autoimmune disorder based on genes inherited Intolerance – The immune system may not be aware of all the antigens present in the inner ear until physical damage releases some of these antigens. As a result, the immune system treats these unfamiliar antigens as foreign and mounts an immune response. Currently, the cross-reactions theory appears to be the favored mechanism of AIED pathogenesis.
Signs and symptoms[edit]
Signs and symptoms of AIED are:
- Progressive hearing loss in both ears
- Typically will begin in one ear and gradually affect the other
- Hearing loss may begin suddenly
- Tinnitus (ringing or buzzing in ears)
- Decrease in word recognition capability
- Loss of balance (vestibular symptoms)
- Degree of balance loss can change throughout the course of the disease
Diagnosis[edit]
Since AIED symptoms are fairly common to many hearing loss disorders, it may be difficult to diagnose AIED without performing multiple medical tests. Some examples of these tests include:
- Hearing Tests for Progressive Hearing and Balance loss
- Audiometry (measure of hearing acuity and sound intensity)
- Rotatory Chair Test (determines if inner ear is responsible for balance loss)
- Electrocochleography (ECOG) (recording of electrical potential in inner ear due to sound)
- Blood Tests for General Autoimmune Diseases
- Erythrocyte sedimentation rate (test for inflammation)
- Rheumatoid Factor (indicator of autoimmune disorders)
There are also blood tests specific to inner ear disorders:
- Anti-cochlear antibody test (testing for antibodies against cochlear cells)
- Lymphocyte Transformation Assay (testing whether an individual has developed a T-cell response against a certain drug)
Though it has also been proposed that the use of anti heat shock protein 70 antibodies may be useful in the detection and diagnosis of AIED.
Treatment[edit]
AIED treatment is a rapidly changing field. Several medical therapies have been proposed in the treatment of AIED, with corticosteroid therapy being the most effective. However, corticosteroid therapy (specifically with prednisone and dexamethasone) has demonstrated limited effectiveness in some patients, suggesting the need for novel treatment methods. The goal of most AIED treatments is to administer corticosteroids over a certain period of time, re-evaluate hearing at each appointment, and eventually taper off corticosteroid administration. Ideally, patients can be tapered off with hearing fully recovered, though this is the least likely outcome. Often, tumor necrosis factor-α (TNF-α) inhibitors must be administered alongside corticosteroids to achieve a favorable outcome and eventual end to corticosteroid treatment. Recent papers have indicated that the TNF-α inhibitor, infliximab, has the potential to allow for sustained patient improvement and alleviation of symptoms. Cytotoxic agents such as cyclophosphamide and methotrexate have been used in AIED treatment in the past; however, findings have suggested limited symptom alleviation from these drugs.
NIH genetic and rare disease info[edit]
Autoimmune inner ear disease is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Autoimmune inner ear disease
|


